



NEXUS Surgical And Medicare Limited

Regd. Address: Gala No. 4, Building No. 1, Saarthak, Square Ind Park, Sativali,
Vasai (East), Palghar - 401 208. | Tel.: 8433598185 | Email: nexuscomm92@gmail.com
Website: www.nexusmed.co.in | CIN: L33100MH1992PLC328367

Date: 14th November, 2024

To,
BSE Limited
Corporate Relation Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001.

Script Code - 538874

Sub: Outcome of Board Meeting held on Thursday, 14th November, 2024

Dear Sir / Madam,

We would like to inform you that the meeting of the Board of Directors of **Nexus Surgical and Medicare Limited** was held on **Thursday, 14th November, 2024 at 05:00 p.m.** at the Registered Office of the Company situated at Gala No. 4, Saarthak, Building No. 1, Square Industrial Park, Tungarphata, Vasai (East), Palghar - 401 208 and transacted the following business:

1. The Board of Directors of the Company has approved the unaudited quarterly financial results of the Company for the quarter and half year ended 30th September, 2024. A copy of the same alongwith Limited Review Report on the said results is enclosed herewith.

The meeting commenced at 05:00 p.m. and concluded at 05:30 p.m.

Kindly take the same on your records.

Thanking you.
Yours faithfully,
For Nexus Surgical and Medicare Limited

Ram Swaroop Joshi
DIN: 07184085
Managing Director

Encl: as above

Nexus Surgical and Medicare Limited

Statement of Unaudited Financial Results for the Quarter and Half Year ended September 30, 2024

(Rs. in lakh, except equity per share data)

Particulars	Quarter ended on			Half Year Ended on		Year ended
	Sep 30, 2024 (Unaudited)	June 30, 2024 (Unaudited)	Sep 30, 2023 (Unaudited)	Sep 30, 2024 (Unaudited)	Sep 30, 2023 (Unaudited)	Mar 31, 2024 (Audited)
Income:						
Sales and Services	99.49	176.03	36.95	275.52	143.03	347.42
Other Income	-	-	1.85	-	2.60	2.68
Total Income	99.49	176.03	38.80	275.52	145.63	350.11
Expenses						
Purchase of stock-in-trade	62.98	21.11	21.77	84.09	29.44	92.51
Change in inventories of stock-in-trade	(26.28)	34.42	(11.57)	8.14	(13.15)	(33.15)
Employee benefits expense	4.87	5.51	5.56	10.38	10.87	23.99
Depreciation and amortization expense	0.10	0.10	0.04	0.20	0.07	0.19
Other expense	30.31	102.89	12.03	133.20	103.83	237.49
Total Expenses	71.98	164.04	27.83	236.02	131.06	321.04
Profit/(loss) before Exceptional Item and Tax	27.51	11.99	10.97	39.50	14.57	29.07
Exceptional Item Income/(Loss)	-	-	-	-	-	-
Profit/(loss) before Tax	27.51	11.99	10.97	39.50	14.57	29.07
Current Tax	6.94	3.00	2.77	9.94	3.67	7.70
Tax for earlier years	-	-	-	-	-	(0.08)
Deferred Tax	-	-	0.06	-	0.06	0.12
Tax expenses	6.94	3.00	2.83	9.94	3.72	7.74
Profit/(loss) for the period	20.56	8.99	8.14	29.56	10.85	21.33
Other comprehensive income (OCI), net of income tax						
Items that will not be reclassified to profit or loss	-	-	-	-	-	-
Items that will be reclassified to profit or loss	-	-	-	-	-	-
Total other comprehensive income, net of income tax	-	-	-	-	-	-
Total other comprehensive income for the period	20.56	8.99	8.14	29.56	10.85	21.33
Paid-up Equity Share Capital (Equity shares of Rs. 10 each)	547.19	547.19	547.19	547.19	547.19000	547.19
Reserve excluding revaluation reserves						(490.56)
Basic and Diluted Earning Per Share (not annualized)	0.38	0.16	0.15	0.54	0.20	0.39

Notes:

- The above Unaudited Financial result have been reviewed and recommended by the audit committee and have been approved by the Board of Directors at their meeting held on November 14, 2024. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid results.
- The aforesaid unaudited financial results for the quarter and half year ended September 30, 2024 has been prepared in accordance with Companies (Indian Accounting Standard) Rule, 2015 as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and in terms of Regulation 33 and Regulation 52 of SEBI (Listing Obligation and disclosure Requirements) Regulations, 2015, as amended.
- The Company has only one operating segment, namely Financial Activity, & is governed by similar set of risk ad return hence disclosure requirements as per Ind AS 108 are not applicable.
- Previous period figures have been restated or regrouped or rearranged wherever necessary, to make them comparable.
- The company has not received any shareholder / investors complaints during the quarter ended September 30, 2024.

For and on behalf of Board of Directors of
Nexus Surgical and Medicare Limited

Ram Swaroop Joshi
Managing Director
DIN: 07184085

Vasai
November 14, 2024

Nexus Surgical and Medicare Limited

Note 6: Statement of Assets and Liabilities

Particulars	(Rs. in lakhs)	
	As at Sep 30, 2024 (Unaudited)	As at Mar 31, 2024 (Audited)
ASSETS		
Non-current assets		
(a) Property, Plant and Equipment	2.59	2.08
(b) Income Tax Assets (Net)	-	2.56
(c) Deferred Tax Assets (Net)	0.81	0.81
Current assets		
(a) Inventories	32.10	40.24
(b) Financial Assets:		
(i) Trade receivables	120.42	75.23
(ii) Cash and cash equivalents	7.51	23.41
(iii) Loans and Advances	25.28	10.28
(iv) Other Financial Assets	4.25	4.25
(c) Other current Assets	11.57	21.75
Total Assets	204.52	180.62
EQUITY AND LIABILITIES		
Equity		
(a) Equity Share capital	547.19	547.19
(b) Other Equity	(461.01)	(490.56)
LIABILITIES		
Current liabilities		
(a) Financial Liabilities		
(i) Trade payables	113.23	123.73
(b) Other current liabilities	0.23	0.27
(c) Current tax liability (net)	4.88	-
Total Equity and Liabilities	204.52	180.62

Nexus Surgical and Medicare Limited

Note 7: Statement of Cash Flow

Particulars	<i>(Rs. in lakhs)</i>	
	As at Sep 30, 2024	As at Sep 30, 2023
Profit before tax	39.50	14.57
Adjustment to reconcile net profit to net cash provided by operating activities		
Interest Income	-	(1.97)
Depreciation expenses	0.20	0.07
	39.70	12.67
Change in assets & liabilities		
Trade receivables	(45.18)	(27.13)
Inventories	8.14	(13.15)
Other Assets	12.74	(9.72)
Trade payables	(10.50)	6.50
Other financial & other liabilities	4.84	29.93
Cash generated from operating activities	9.74	(0.90)
Income Tax Paid	9.94	-
Net Cash generated from operating activities	(0.20)	(0.90)
Cash flow from investing activities		
Interest Income	-	1.97
Loans & advances	(15.00)	-
Assets Purchase	(0.71)	-
	(15.71)	1.97
Cash flow from financing activities	-	-
Net cash generated	(15.91)	1.07
Cash & cash equivalents at the beginning of the year	23.41	65.11
Cash & cash equivalents at the end of the year	7.51	66.18
Reconciliation of cash and cash equivalents as per the cash flow statement		
Cash and cash equivalents as per above comprise of the following		
Cash and cash equivalents	7.51	66.18
Balances per statement of cash flows	7.51	66.18



**INDEPENDENT AUDITOR'S REVIEW REPORT ON REVIEW OF INTERIM STANDALONE FINANCIAL RESULTS FOR
THE QUARTER AND SIX MONTHS ENDED 30 SEPTEMBER 2024.**

To
The Board of Directors
Nexus Surgical and Medicare Limited

I have reviewed the accompanying Statement of unaudited standalone financial results of **Nexus Surgical and Medicare Limited**, for the quarter and half year ended September 30, 2024, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, "Interim Financial Reporting" ("Ind AS 34"), prescribed under section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. My responsibility is to issue a report on the Statement based on my review.

I conducted my review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that I plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. I have not performed an audit and accordingly, I do not express an audit opinion.

Based on my review conducted as above, nothing has come to my attention that causes me to believe that the accompanying Statement prepared in accordance with applicable accounting standards and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

For and on behalf of
Satya Prakash Natani & Co.
Chartered Accountants
Firm's Registration No.: 115438W



Satya Prakash Natani
Partner
Membership No.: 048091
Mumbai
November 14, 2024
UDIN: 24048091BKAQDA7065

Office: 505, Goyal Trade Center, Sona Cinema, Shantivan, Borivali (E), Mumbai-400 066.
Tel.: 2897 6621 Email: spnatani@gmail.com Web.: www.casprnatani.in